Render Target: STATIC
Render Timestamp: 2024-11-21T13:26:30.950Z
Commit: 5c4accf06eb7154018ba3f54329c7590f97f534a
XML generation date: 2024-09-30 01:59:22.602
Product last modified at: 2024-11-11T13:15:46.800Z
1% for the planet logo
PDP - Template Name: Monoclonal Antibody
PDP - Template ID: *******c5e4b77
R Recombinant
Recombinant: Superior lot-to-lot consistency, continuous supply, and animal-free manufacturing.

Cadherin-17 (E5J8Z) Rabbit mAb #85724

Filter:
  • WB
  • IHC

    Supporting Data

    REACTIVITY H
    SENSITIVITY Endogenous
    MW (kDa) 120
    Source/Isotype Rabbit IgG
    Application Key:
    • WB-Western Blotting 
    • IHC-Immunohistochemistry 
    Species Cross-Reactivity Key:
    • H-Human 

    Product Information

    Product Usage Information

    Application Dilution
    Western Blotting 1:1000
    Immunohistochemistry (Paraffin) 1:250 - 1:1000

    Storage

    Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/mL BSA, 50% glycerol, and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.

    For a carrier free (BSA and azide free) version of this product see product #53536.

    Protocol

    Specificity / Sensitivity

    Cadherin-17 (E5J8Z) Rabbit mAb recognizes endogenous levels of total cadherin-17 protein.

    Species Reactivity:

    Human

    Source / Purification

    Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues near the carboxy terminus of human cadherin-17 protein.

    Background

    Cadherin-17/Liver-Intestine-cadherin (CDH17/LI-cadherin) is a type-I transmembrane glycoprotein that belongs to the 7D-cadherin superfamily. Unlike classical cadherins, CDH17 is characterized by an extracellular domain with seven cadherin repeats and a short intracellular domain (1). CDH17 is a calcium-dependent homotypic cell-cell adhesion molecule that, under normal physiologic conditions in humans, is selectively expressed on the basolateral surface of epithelia lining the small intestine and colon (2). Research studies have demonstrated that CDH17 is aberrantly overexpressed in human gastric cancer and may serve as a novel oncogenic biomarker for this disease (3,4). At the molecular level, research studies have suggested that CDH17 exerts its oncogenicity in the context of gastric cancer through its ability to engage both NF-κB and MAPK signaling cascades (5,6).
    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.